Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 30, 2023

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplantation vs Fingolimod, Natalizumab, and Ocrelizumab Therapies in Patients With Highly Active Relapsing–Remitting MS

JAMA Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Neurology
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 2023 May 15;[EPub Ahead of Print], T Kalincik, S Sharmin, I Roos, et al

Further Reading